Chana Abrams
Medical · Baltimore, MDNPI 1982843157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 26.3% of the total.
Across 353 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$852
- Bayer$739
- Novo Nordisk$391
- Boehringer Ingelheim$345
- Amgen$310
- plus $3K from 40 others
What the payments were for
- Food & beverage$6,97699%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,048 in reported general payments places this provider in the 85th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $78,471 |
| EliquisApixaban | 45 | $45,640 |
| JardianceEmpagliflozin | 35 | $36,593 |
| FarxigaDapagliflozin Propanediol | 34 | $35,741 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $32,290 |
| MounjaroTirzepatide | 13 | $23,216 |
| KerendiaFinerenone | 25 | $22,678 |
| Repatha SureclickEvolocumab | 13 | $18,545 |
| XareltoRivaroxaban | 12 | $17,106 |
| TrulicityDulaglutide | 11 | $16,785 |
| MyrbetriqMirabegron | 18 | $8,887 |
| Olmesartan Medoxomil | 29 | $3,877 |
| Rosuvastatin Calcium | 150 | $3,065 |
| SynthroidLevothyroxine Sodium | 26 | $2,674 |
| Amlodipine Besylate | 251 | $2,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $391 | $78,47163 claims |
| PfizerEliquis | $116 | $45,64045 claims |
| Lilly USA, LLCMounjaro, Trulicity | $852 | $40,00124 claims |
| Boehringer IngelheimJardiance | $345 | $36,59335 claims |
| AstraZenecaFarxiga | $217 | $35,74134 claims |
| BayerKerendia | $739 | $22,67825 claims |
| Johnson & JohnsonXarelto | $19 | $17,10612 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $8,88718 claims |
| AbbVieSynthroid | $1,854 | $2,67426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 medical providers in Maryland.
Other medical in Baltimore
- Sarah SagorskyBaltimore$68K
- Maribeth HatalskiBaltimore$11K
- Edward MikulaBaltimore$11K
- Natalie OrbachBaltimore$10K
- Helen ReidlerBaltimore$10K
- Michelle DanielsBaltimore$9K
- Joshua PertmanBaltimore$7K
- Victoria TrottStevensville$94K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.